CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.

Saved in:
Bibliographic Details
Title: CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.
Authors: Oh-Hohenhorst SJ; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.; Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Tilki D; Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Ahlers AK; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.; Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Suling A; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hahn O; Department of Urology, University Medical Center Goettingen, Göttingen, Germany., Tennstedt P; Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Matuszcak C; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Maar H; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Labitzky V; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Hanika S; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Starzonek S; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Baumgart S; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Strasse 40, 37075, Goettingen, Germany.; Research & Development, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany., Johnsen SA; Gene Regulatory Mechanisms and Molecular Epigenetics Lab, Gastroenterology Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Kluth M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Sirma H; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Huland H; Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schumacher U; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany., Lange T; Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. to.lange@uke.de.
Source: Cancer gene therapy [Cancer Gene Ther] 2022 Jan; Vol. 29 (1), pp. 49-61. Date of Electronic Publication: 2021 Jan 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5500
DOI:10.1038/s41417-020-00288-z